Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Nemonoxacin in Treating Elderly Patients With CAP
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Luminarie
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TaiGen Out-Licensed Taigexyn® to Luminarie Canada for Canada, Australia and New Zealand
Details : Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.
Product Name : Taigexyn
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 30, 2020
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Luminarie
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : OCT Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 11, 2018
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : OCT Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 05, 2017
Lead Product(s) : Nemonoxacin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 21, 2016
Lead Product(s) : Nemonoxacin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Huashan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 13, 2015
Lead Product(s) : Nemonoxacin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Huashan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 31, 2014
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : QPS Holdings | R&G PharmaStudies Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 18, 2013
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : QPS Holdings | R&G PharmaStudies Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Qualitix Clinical Research | Parexel | PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 08, 2012
Lead Product(s) : Nemonoxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Qualitix Clinical Research | Parexel | PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study on Oral Nemonoxacin Malate Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 15, 2011
Lead Product(s) : Nemonoxacin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable